|
1
|
Sariego J: Breast cancer in the young
patient. Am Surg. 76:1397–1400. 2010.
|
|
2
|
Ban KA and Godellas CV: Epidemiology of
breast cancer. Surg Oncol Clin North Am. 23:409–422. 2014.
View Article : Google Scholar
|
|
3
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar
|
|
4
|
DeSantis C, Ma J, Bryan L and Jemal A:
Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014.
View Article : Google Scholar
|
|
5
|
de Boer M, van Dijck JA, Bult P, Borm GF
and Tjan-Heijnen VC: Breast cancer prognosis and occult lymph node
metastases, isolated tumor cells, and micrometastases. J Natl
Cancer Inst. 102:410–425. 2010.PubMed/NCBI
|
|
6
|
de Ruijter TC, Veeck J, de Hoon JP, van
Engeland M and Tjan-Heijnen VC: Characteristics of triple-negative
breast cancer. J Cancer Res Clin Oncol. 137:183–192.
2011.PubMed/NCBI
|
|
7
|
Yadav BS, Sharma SC, Chanana P and Jhamb
S: Systemic treatment strategies for triple-negative breast cancer.
World J Clin Oncol. 5:125–133. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Augsten M: Cancer-associated fibroblasts
as another polarized cell type of the tumor microenvironment. Front
Oncol. 4:622014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Guan J and Chen J: Mesenchymal stem cells
in the tumor microenvironment. Biomed Rep. 1:517–521.
2013.PubMed/NCBI
|
|
10
|
Ji RC: Hypoxia and lymphangiogenesis in
tumor microenvironment and metastasis. Cancer Lett. 346:6–16. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Blagosklonny MV: Antiangiogenic therapy
and tumor progression. Cancer Cell. 5:13–17. 2004. View Article : Google Scholar
|
|
12
|
Jochmanova I, Yang C, Zhuang Z and Pacak
K: Hypoxia-inducible factor signaling in pheochromocytoma: turning
the rudder in the right direction. J Natl Cancer Inst.
105:1270–1283. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Martin SK, Diamond P, Gronthos S, Peet DJ
and Zannettino AC: The emerging role of hypoxia, HIF-1 and HIF-2 in
multiple myeloma. Leukemia. 25:1533–1542. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mooberry SL: New insights into
2-methoxyestradiol, a promising antiangiogenic and antitumor agent.
Curr Opin Oncol. 15:425–430. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Morishita R, Higaki J, Tomita N and
Ogihara T: Application of transcription factor ‘decoy’ strategy as
means of gene therapy and study of gene expression in
cardiovascular disease. Circ Res. 82:1023–1028. 1998. View Article : Google Scholar
|
|
16
|
Osako MK, Nakagami H and Morishita R:
Modification of decoy oligodeoxynucleotides to achieve the
stability and therapeutic efficacy. Curr Top Med Chem.
12:1603–1607. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hoel AW and Conte MS: Edifoligide: a
transcription factor decoy to modulate smooth muscle cell
proliferation in vein bypass. Cardiovasc Drug Rev. 25:221–234.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu M, Wang F, Wen Z, Shi M and Zhang H:
Blockage of STAT3 signaling pathway with a decoy
oligodeoxynucleotide inhibits growth of human ovarian cancer cells.
Cancer Invest. 32:8–12. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
De Stefano D, Coletta C, Bianca Rd, et al:
A decoy oligonucleotide to NF-kappaB delivered through inhalable
particles prevents LPS-induced rat airway inflammation. Am J Respir
Cell Mol Biol. 49:288–295. 2013.PubMed/NCBI
|
|
20
|
Sen M, Thomas SM, Kim S, et al:
First-in-human trial of a STAT3 decoy oligonucleotide in head and
neck tumors: implications for cancer therapy. Cancer Discov.
2:694–705. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Imai M, Ishibashi H, Nariai Y, Kanno T,
Sekine J, Onimaru M and Mori Y: Transfection of hypoxia-inducible
factor-1 decoy oligodeoxynucleotides suppresses expression of
vascular endothelial growth factor in oral squamous cell carcinoma
cells. J Oral Pathol Med. 41:675–681. 2012. View Article : Google Scholar
|
|
22
|
Benita Y, Kikuchi H, Smith AD, Zhang MQ,
Chung DC and Xavier RJ: An integrative genomics approach identifies
hypoxia inducible factor-1 (HIF-1)-target genes that form the core
response to hypoxia. Nucleic Acids Res. 37:4587–4602. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar
|
|
24
|
Engebraaten O, Vollan HK and Borresen-Dale
AL: Triple-negative breast cancer and the need for new therapeutic
targets. Am J Pathol. 183:1064–1074. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mahamodhossen YA, Liu W and Rong-Rong Z:
Triple-negative breast cancer: new perspectives for novel
therapies. Med Oncol. 30:6532013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li S and Li Q: Cancer stem cells and tumor
metastasis. Int J Oncol. 44:1806–1812. 2014.
|
|
28
|
Tomita N, Kashihara N and Morishita R:
Transcription factor decoy oligonucleotide-based therapeutic
strategy for renal disease. Clin Exp Nephrol. 11:7–17. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tomita N, Ogihara T and Morishita R:
Therapeutic potential of decoy oligonucleotides strategy in
cardiovascular diseases. Expert Rev Cardiovasc Ther. 1:463–470.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
De Stefano D, De Rosa G and Carnuccio R:
NF kappaB decoy oligonucleotides. Curr Opin Mol Ther. 12:203–213.
2010.PubMed/NCBI
|
